The role of brain cholesterol and its oxidized products in alzheimer's disease

Current Alzheimer Research

Volumn 13, Issue 2, 2016, Pages 198-205

  Giudetti, Anna Maria ^a   Romano, Adele ^b   Lavecchia, Angelo Michele ^b   Gaetani, Silvana ^b  

^a UNIVERSITY OF SALENTO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer s disease; Antioxidants; Blood brain barrier; Brain; Cholesterol metabolism; Oxysterols; Statins

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; NUTRACEUTICAL; OXYSTEROL;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; HOMEOSTASIS; HUMAN; NEURITE; PRIORITY JOURNAL; SYNAPTOGENESIS; ANIMAL; BRAIN; METABOLISM; OXIDATION REDUCTION REACTION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CHOLESTEROL; HUMANS; OXIDATION-REDUCTION;

EID: 84959325219     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150921103426     Document Type: Article

References (89)

1. Wood WG, Li L, Muller WE, Eckert GP. Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. J Neurochem 129: 559-72 (2014).
2. Myant NB. The Biology of Cholesterol and Related Steroids. London: William Heinemann Medical Books Ltd (1981).
3. McGarry JD. Lipid metabolism I: utilization and storage of energy in lipid form. In: Devlin TM, Ed. Textbook of Biochemistry With Clinical Correlations. New York: Wiley-Liss; pp. 387-473 (1992).
4. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol 93: 27-42 (2008).
5. Attie AD, Kastelein JP, Hayden MR. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res 42: 1717-1726 (2001).
6. Barter PJ, Brewer HB, Chapman MJ, Hennekans CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23: 160-167 (2003).
7. Vance JE, Karten B, Hayashi H. Lipid dynamics in neurons. Biochem Soc Trans 34: 399-403 (2006).
8. Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 24: 806-15 (2004).
9. Orth M, Bellosta S. Cholesterol: its regulation and role in central nervous system disorders. Cholesterol 2012: 292598 (2012).
10. Pfrieger FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 25: 72-78 (2003).
11. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller E C, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294: 1354-1357 (2001).
12. Waterham HR. Defects of cholesterol biosynthesis. FEBS Lett 580: 5442-5449 (2006).
13. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 23: B72-B78 (2000).
14. Birkenmeier G, Grosche J, Reichenbach A. Immunocytochemical demonstration of alpha 2-M-R/LRP on Muller (glial) cells isolated from rabbit and human retina. Neuroreport 8: 149-151 (1996).
15. Jung-Testas I, Weintraub H, Dupuis D, Eychenne B, Baulieu EE, Robel P. Low density lipoprotein-receptors in primary cultures of rat glial cells. J Steroid Biochem Mol Biol 42: 597-560 (1992).
16. Bjorkhem I, Lutjohann D, Diczfalusy U, Stahle L, Ahlborg G, Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 39: 1594-1600 (1998).
17. Heverin M, Meaney S, Lutjohann D, Diczfalusy U, Wahren J, Bjorkhem I. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 46: 1047-1052 (2005).
18. Meaney S, Bodin K, Diczfalusy U, Bjorkhem I. On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. J Lipid Res 43: 2130-2135 (2002).
19. Lutjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, Bjorkhem I. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 93: 9799-9804 (1996).
20. Lund EG, Guileyardo JM, Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96: 7238-7243 (1999).
21. Bretillon L, Diczfalusy U, Bjorkhem I, Maire MA, Martine L, Joffre C, et al. Cholesterol-24S-hydroxylase (CYP46A1) is specifically expressed in neurons of the neural retina. Curr Eye Res 32: 361-366 (2007).
22. Edwards PA, Kennedy MA, Mak PA. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul Pharmacol 38: 249-256 (2002).
23. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 16: 459-481 (2000).
24. Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, et al. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol 16: 1378-1385 (2002).
25. Yue L, Mazzone T. Peroxisome proliferator-activated receptor γ stimulation of adipocyte ApoE gene transcription mediated by the liver receptor X pathway. J Biol Chem 284: 10453-10461 (2009).
26. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278: 22980-22988 (2003).
27. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein Econtaining lipoproteins. Biochim Biophys Acta 917: 148-61 (1987).
28. Grehan S, Tse E, Taylor JM. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci 21: 812-22 (2001).
29. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9: 106-18 (2013).
30. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer’s disease. Subcell Biochem 65: 329-52 (2012).
31. Corder EH, Woodbury MA. Genetic heterogeneity in Alzheimer's disease: a grade of membership analysis. Genet Epidemiol 10: 495-9 (1993).
32. Strittmatter WJ, Huang DY, Bhasin R, Roses AD, Goldgaber D. Avid binding of beta A amyloid peptide to its own precursor. Exp Neurol 122: 327-34 (1993).
33. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 269: 23403-6 (1994).
34. LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J Biol Chem 270: 9039-42 (1995).
35. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 10: 241-52 (2011).
36. Fan J, Donkin J, Wellington C. Greasing the wheels of Abeta clearance in Alzheimer’s disease: the role of lipids and apolipoprotein E. Biofactors 35: 239-48 (2009).
37. Burns MMJ. Unraveling the Role of Lipid Metabolism in Alzheimer’s Disease. UBCMJ 3: 27-28 (2011)
38. Tai LM, Mehra S, Shete V, Estus S, Rebeck GW, Bu G, et al. Soluble apoE/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener doi: 10.1186/1750-1326-9-2 (2014).
39. Chang TY, Chang CC, Ohgami N, Yamauchi Y. Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol 22: 129-157 (2006).
40. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 3: 905-912 (2001).
41. Bhattacharyya R, Kovacs DM. ACAT inhibition and amyloid beta reduction. Biochim Biophys Acta 1801: 960-5 (2010).
42. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron 44: 227-238 (2004).
43. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 12: 284-296 (2011).
44. Igbavboa U, Avdulov NA, Schroeder F, Wood WG. Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J Neurochem 66: 1717-1725 (1996).
45. Barenholz Y. Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcell Biochem 37: 167-215 (2004).
46. Cordy JM, Hooper, NM, Turner AJ. The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol 23: 111-112 (2006).
47. Morell P, Jurevics H. Origin of cholesterol in myelin. Neurochem Res 21:463-470 (1996).
48. Wood WG, Li L, Muller WE, Eckert GP. Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. J Neurochem 129: 559-72 (2014).
49. Sparks DL, Scheff SW, Liu H, Landers T, Danner F, Coyne CM, et al. Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. J Neurol Sci 138: 97-104 (1996).
50. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, et al. A cholesterol-lowering drug reduces betaamyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8: 890-899 (2001).
51. Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas- Bryant T, et al. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 19: 155-161 (2002).
52. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 356: 1627-1631 (2000).
53. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3- hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443 (2000).
54. Petanceska SS, DeRosa S, Sharma A, Diaz N, Duff K, Tint SG, et al. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci 20: 395-406 (2003).
55. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 19: 5: 20 (2007).
56. Sparks DL, Liu H, Gross DR, Scheff SW. Increased density of cortical apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol. Neurosci Lett 187: 142-44 (1995).
57. Mastrocola R, Guglielmotto M, Medana C, Catalano MG, Cutrupi S, Borghi R, et al. Dysregulation of SREBP2 induces BACE1 expression. Neurobiol Dis 44: 116-24 (2011).
58. Bjorkhem I, Cedazo-Minguez A, Leoni V, Meaney S. Oxysterols and neurodegenerative diseases. Mol Aspects Med 30: 171-179 (2009).
59. Brown J 3rd, Theisler C, Silberman S, Magnuson D, Gottardi- Littell N, Lee JM, et al. Differential expression of cholesterol hydroxylase in Alzheimer’s disease. J Biol Chem 279: 34674-81 (2004).
60. Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L, et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J Lipid Res 45: 186-93 (2004).
61. Meaney S, Heverin M, Panzenboeck U, Ekstrom L, Axelsson M, Andersson U, et al. Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3- oxo-4-cholestenoic acid. J Lipid Res 48: 944-951 (2007).
62. Hughes MT. Brain cholesterol metabolism, oxysterols, and dementia. J Alzheimer disease 33: 891-911 (2013).
63. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 110(5): 597-603 (2002).
64. Dasari B, Prasanthi JRP, Marwarha G, Singh BB, Ghribi O. The oxysterol 27-hydroxycholesterol increases beta-amyloid and oxidative stress in retinal pigment epithelial cells. BMC Ophthalmol 10: 22 (2010).
65. Yau JL, Rasmuson S, Andrew R, Graham M, Noble J, Olsson T, et al. Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease. Neuroscience 121: 307-314 (2003).
66. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118 (2005).
67. Polidori MC. Oxidative stress and risk for Alzheimer’s disease: clues to prevention and therapy. J Alzheimers Dis 6: 185-91 (2004).
68. Barone E, Cenini G, Di Domenico F, Martin S, Sultana R, Mancuso C, et al. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res 63: 172-180 (2011).
69. Butterfield DA, Barone E, Mancuso C. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res. 64: 180-186 (2011).
70. Barone E, Mancuso C, Di Domenico F, Sultana R, Murphy MP, Head E, Butterfield DA. Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem. 120: 135-146 (2012).
71. Butterfield DA, Barone E, Di Domenico F, Cenini G, Sultana R, Murphy MP, Mancuso C, Head E. Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int J Neuropsychopharmacol. 15: 981-987 (2012).
72. Barone E, Di Domenico F, Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol 88: 605-616 (2014).
73. Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J 13: 17 (2014).
74. D'Agostino G, Russo R, Avagliano C, Cristiano C, Meli R, Calignano A. Palmitoylethanolamide protects against the amyloid-β25- 35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology 37: 1784-1792 (2012).
75. Scuderi C, Steardo L. Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease. CNS Neurol Disord Drug Targets 12(1): 62- 69 (2013).
76. Tomasini MC, Borelli AC, Beggiato S, Ferraro L, Cassano T, Tanganelli S, Antonelli T. Differential Effects of Palmitoylethanolamide against Amyloid-β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice. J Alzheimers Dis. doi: 10.3233/JAD-143039 (2015).
77. Dipasquale P, Romano A, Cianci S, Righetti L, Gaetani S. Oleoylethanolamide: A new player in energy metabolism control. Role in food intake. Drug discovery today: disease mechanisms 7: e169-e174 (2010).
78. Fan A, Wu X, Wu H, Li L, Huang R, Zhu Y, Qiu Y, Fu J, Ren J, Zhu C. Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL. PLoS One 9: e85337 (2014).
79. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer’s disease. Lancet Neurol 3: 579-587 (2004).
80. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287: 3223-3229 (2002).
81. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287: 3230-3237 (2002).
82. Kiraly SJ, Kyraly M, Hawe RD, Makhani N. Vitamin D as a neuroactive substaence: review. Sci World J 6: 125-139 (2006).
83. Mandel S, Youdim MB. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med 37: 304-317 (2004).
84. Simonyi A, Wang Q, Miller RL, Yusof M, Shelat PB, Sun AY, Sun GY. Polyphenols in cerebral ischemia: novel targets for neuroprotection. Mol Neurobiol 31: 135-147 (2005).
85. Calabrese V, Cornelius C, Mancuso C, Barone E, Calafato S, Bates T, et al. Vitagenes dietary antioxidants and neuroprotection in neurodegenerative diseases. Front Biosci 14: 376-397 (2009).
86. Joseph J, Cole G, Head E, Ingram D. Nutrition, brain aging, and neurodegeneration. J Neurosci 29: 12795-12801 (2009).
87. Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules 15: 7792-7814 (2010).
88. Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta(25-35). Behav Brain Res 180: 139-145 (2007).
89. Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 113: 154-164 (2007).